Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
Aphreseller (Buy-herbal.com), an online seller based in Flushing, New York, has voluntarily recalled all lots of Kian Pee Wan capsules after testing identified the presence of undeclared drug ingredients dexamethasone and cyproheptadine.
The product, marketed as a dietary supplement for weight gain and appetite stimulation, was distributed nationwide through online sales, including eBay. Because it contains active pharmaceutical ingredients that are not disclosed on the label, the product is considered an unapproved drug for which safety and effectiveness have not been established.
Consumers are advised to stop using the product immediately. Kian Pee Wan capsules are packaged in a white bottle with a beige label and contain 30 capsules per container.
Health Risk
The presence of undeclared drug ingredients presents significant health risks.
Dexamethasone, a corticosteroid, is associated with a range of serious adverse effects, including immune suppression, elevated blood sugar levels, muscle injury, psychiatric symptoms, and increased risk of cardiovascular events. Prolonged or high-dose exposure may also suppress adrenal function, potentially leading to serious or life-threatening complications. In addition, abrupt discontinuation can result in withdrawal symptoms.
Cyproheptadine, a prescription antihistamine, may cause sedation, dizziness, fatigue, dry mouth, gastrointestinal disturbances, urinary retention, and blurred vision. Because consumers are unaware of its presence, the risk of unintended exposure and drug interactions is increased.
Distribution and Consumer Guidance
The recalled product was sold nationwide via online platforms. Aphreseller is notifying customers through this announcement and direct communication where possible and is facilitating product returns.
Consumers who have purchased Kian Pee Wan capsules should discontinue use immediately and may return the product to the point of purchase for a refund. Individuals who have used the product and are experiencing symptoms should contact a healthcare provider.
Questions regarding the recall can be directed to the company via phone at 347-313-8605 or email at greatremedy68@gmail.com, Monday through Friday from 10:00 a.m. to 6:00 p.m. Eastern Time. Adverse events may also be reported to the FDA’s MedWatch program.
MDP Observations and Analysis
This recall reflects a recurring and high-risk compliance issue within the dietary supplement market: the presence of undeclared pharmaceutical ingredients in products marketed as supplements.
Unlike labeling errors or manufacturing inconsistencies, this type of violation represents a fundamental breakdown in regulatory classification and product integrity. Products that contain active drug substances such as dexamethasone and cyproheptadine cannot legally be marketed as dietary supplements. Their presence transforms the product into an unapproved drug, subject to significantly different regulatory requirements.
These cases are frequently associated with products marketed for outcomes such as weight gain, sexual enhancement, or rapid therapeutic effects, areas where consumer demand may incentivize the inclusion of pharmacologically active substances. However, the lack of disclosure removes the consumer’s ability to assess risk, including potential drug interactions, contraindications, and dosage-related effects.
From a regulatory and quality perspective, this type of issue typically indicates one or more of the following. Absence of ingredient verification and supplier control, lack of formulation oversight and documentation, intentional adulteration to achieve perceived efficacy, and / or failure to implement appropriate quality system controls.
For regulators, these products represent a significant enforcement priority due to the potential for serious and unpredictable health outcomes. For manufacturers and distributors operating legitimately within the supplement space, these cases underscore the importance of ingredient transparency, supplier qualification, and regulatory classification discipline.
Ultimately, this recall highlights the distinction between compliant supplement manufacturing and products that operate outside established regulatory frameworks. Maintaining that distinction is essential for both consumer safety and market integrity.
Links
Read the FDA’s announcement here.
One Contaminated Alcohol Pad, Multiple Recalls
A Lesson in Medical Device Supply Chain Quality At first glance, Cardinal Health's recent recall of Webcol™ Alcohol Prep Pads appears straightforward. A commonly used healthcare product was found to be contaminated with Paenibacillus phoenicis, creating a potential...
Early Alert: Windstone Medical Recall for Convenience Kits
FDA Warns of Convenience Kits Containing Recalled Cardinal Health Alcohol Pads The FDA has issued an Early Alert regarding several medical convenience kits distributed by Windstone Medical Packaging, Inc. that contain alcohol prep pads previously recalled by Cardinal...
Webcol Alcohol Prep Pads Recall Due to Microbial Contamination
Cardinal Health Recalls Alcohol Prep Pads Over Infection Risk Concerns Cardinal Health has issued a voluntary nationwide recall of select lots of its Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol) after testing identified microbial contamination with...
FDA Issues Warning Letter for Modifications to Infant Products
FDA Issues Warning Letter to Happiest Baby Over SNOO Smart Sleeper Modifications and Quality System Deficiencies The U.S. Food and Drug Administration has issued a Warning Letter to Happiest Baby, Inc., manufacturer of the SNOO Smart Sleeper, citing unapproved device...
FDA Expands Draeger Atlan Anesthesia Workstation Correction
More anesthesia machines added to correction for potential ventilation failure The U.S. Food and Drug Administration (FDA) has designated a recent expansion of Draeger, Inc.'s Atlan anesthesia workstation correction as a Class I recall, the agency's most serious...
Warning Letter to Zoll Medical for Major QMS Violations
Warning Letter to Zoll Medical for Major QMS Violations The U.S. Food and Drug Administration has issued a Warning Letter to ZOLL Medical Corporation citing significant Quality System Regulation (QSR) violations involving corrective and preventive action (CAPA),...
